# US 2006/0051740 A1 · Method for the amplification and detection of hbv dna using a transcription based amplification

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0051740 A1
- Document ID: US20060051740A1
- Status: Published application
- Kind: A1
- Application number: 10/471,073
- Filed: 2002-03-06
- Published: 2006-03-09
- Earliest claimed: 2001-03-07
- Inventors: Birgit Alberta Deiman; Inge Frantzen; Arnoldina Margaretha Van Strijp
- Web page: https://patentgrep.com/patent/US20060051740A1

## CPC

- C12Q 1/706: {for hepatitis}
- C12Q 2531/143: Promoter based amplification, e.g. NASBA, 3SR, TAS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention provides a method for the transcription based amplification of a target HBV nucleic acid sequence starting from HBV DNA optionally present in a sample, comprising the steps of,—incubating the sample, suspected to contain HBV, in an amplification buffer with one or more restriction enzymes capable of cleaving the HBV DNA at a selected restriction site, said restriction enzyme creating a defined 3′ end of the said HBV DNA strand(s), a promotor-primer, said promotor-primer having a 5′ region comprising the sequence of a promotor recognized by a DNA-dependent RNA polymerase and a 3′ region complementary to the define 3′ end of the DNA strand, a second or reverse primer, having the opposite polarity of the promotor-primer and comprising the 5′ end of the said target sequence, and in case of HBV ssDNA as the target sequence, a restriction primer,—maintaining the thus created reaction mixture under the appropriate conditions for a sufficient amount of time for a digestion by the restriction enzyme to take place,—subjecting the sample thus obtained to a heat treatment at a temperature and time sufficient to inactivate the restriction enzyme and/or to render at least partially a double strand single stranded,—adding the following reagents to the sample: an enzyme having RNA dependent DNA polymerase activity, an enzyme having DNA dependent DNA polymerase activity, an enzyme having Rnase H activity, an enzyme having RNA polymerase activity, and—maintaining the thus created reaction mixture under the appropriate conditions to a sufficient amount of time for the amplification to take place.

## Claims

### Claim 1

A method for the transcription based amplification of a target HBV nucleic acid sequence starting from HBV DNA optionally present in a sample, said method comprising:
-a) incubating the sample, suspected to contain HBV, in an amplification buffer with
i) one or more restriction enzymes capable of cleaving the HBV DNA at a selected restriction site, said restriction enzyme creating a defined 3′ end of the said HBV DNA strand(s),
ii) a promoter-primer, said promoter-primer having a 5′ region comprising the sequence of a promoter recognized by a DNA-dependent RNA polymerase and a 3′ region complementary to the defined 3′ end of the DNA strand,
iii) a second or reverse primer, having the opposite polarity of the promoter-primer and comprising the 5′ end of the said target sequence, and
iv) in case of HBV ssDNA as the target sequence, a restriction primer;
-b) maintaining the thus created reaction mixture under the appropriate conditions for a sufficient amount of time for a digestion by the restriction enzyme to take place;
-c) subjecting the sample thus obtained to a heat treatment at a temperature and time sufficient to inactivate the restriction enzyme and/or to render at least partially a double strand single stranded;
-d) adding the following reagents to the sample:
i) an enzyme having RNA dependent DNA polymerase activity
ii) an enzyme having DNA dependent DNA polymerase activity
iii) an enzyme having Rnase H activity
iv) an enzyme having RNA polymerase activity; and
e) maintaining the thus created reaction mixture under the appropriate conditions for a sufficient amount of time for the amplification to take place.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the DNA is double stranded HBV DNA.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the DNA is single stranded and the promoter primer and the restriction primer are combined in using a combined promoter and restriction primer comprising a sequence complementary to the region including the restriction site of the target ssDNA and the sequence of a promoter recognized by a DNA-dependent RNA polymerase.

### Claim 4 (depends on 1)

The method according to claim 1 in which nucleoside triphosphates are added to the initial incubation mixture prior to the heat treatment.

### Claim 5 (depends on 1)

The method according to claim 1 in which a reverse transcriptase is used combining the activities of the enzyme having RNA dependent DNA polymerase activity and the enzyme having DNA dependent DNA activity.

### Claim 6 (depends on 1)

The method according to claim 1, in which a reverse transcriptase is used having inherent RNase H activity replacing 3 enzymes, namely the enzyme having RNA dependent DNA polymerase activity, the enzyme having DNA dependent DNA activity as well as the enzyme having Rnase H activity.

### Claim 7 (depends on 1)

The method according to claim 1, in which the incubation temperature is from about 35° C. to about 45° C.

### Claim 8 (depends on 1)

The method according to claim 1 in which to the heating step is carried out at a temperature between about 92° C. and about 98° C.

### Claim 9 (depends on 1)

The method according to claim 1, wherein a restriction enzyme is used that cuts the HBV DNA at a site that is conserved among the different genotypes of HBV.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the restriction site is located in the part of the HBV genome that encodes the surface antigen.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the restriction site is an XbaI site located at nucleotides 247-252 according to the EcoRI site, the BssSI site located at nucleotides 253-258 according to the EcoRI site or an AvrII site located at nucleotides 178-183 according to the EcoRI site, and the restriction enzyme used is the XbaI, BssSI or AvrII restriction enzyme.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the restriction primer is an oligonucleotide containing from about 10 to about 35 nucleotides which hybridize with the HBV target and comprise at least 10 nucleotides flanking the XbaI site located at nucleotides 247-252 according to the EcoRI site, the BssSI site located at nucleotides 253-258 according to the EcoRI site or the AvrII site located at nucleotides 178-183 according to the EcoRI site.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the restriction primer has the oligonucleotide sequence of SEQ ID No. 8 or SEQ ID No 9.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the promoter or forward primer is an oligonucleotide containing from about 10 to about 35 nucleotides which hybridize with the HBV target and comprising at least 10 nucleotides, counted from the cleavage site, of the nucleotide sequence of SEQ ID No 10 in combination with the restriction enzyme XbaI, or of SEQ ID No 11 in combination with BssSI or of SEQ ID No 12 in combination with AvrII, linked to a promoter sequence.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the promoter oligonucleotide has the nucleotide sequence of SEQ ID No 1, SEQ ID No 2, or SEQ ID No. 3.

### Claim 16 (depends on 1)

The method according to claim 1, wherein the amplified HBV nucleic acid is additionally detected using a hybridization probe comprising an oligonucleotide sequence containing from about 10 to about 35 nucleotides which hybridize with the amplified HBV target and comprise at least 10 nucleotides of SEQ ID No. 13 or SEQ ID No 14.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the probe has the oligonucleotide sequence of SEQ ID No 6 or SEQ ID No 7.

### Claim 18 (depends on 1)

The method according to claim 1 wherein the second or reverse primer is an oligonucleotide containing from about 10 to about 35 nucleotides and comprising at least 10 nucleotides of the nucleotide sequence of SEQ ID No. 4 or SEQ ID No. 5.

### Claim 19

An oligonucleotide with an nucleotide sequence selected from the group consisting of SEQ ID No 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, and SEQ ID No. 14.

### Claim 20 (depends on 1)

A set of oligonucleotide primers suitable for use in the amplification of HBV nucleic acid according to the method of claim 1 comprising a promoter primer, wherein the promoter primer is an oligonucleotide containing from about 10 to about 35 nucleotides which hybridize with the HBV target and comprising at least 10 nucleotides, counted from the cleavage site, of the nucleotide sequence of SEQ ID No. 10 in combination with the restriction enzyme XbaI, or of SEQ ID No. 11 in combination with BssSI or of SEQ ID No. 12 in combination with AvrII, linked to a promoter sequence and a reverse primer, wherein the reverse primer is an oligonucleotide containing from about 10 to about 35 nucleotides and comprising at least 10 nucleotides of the nucleotide sequence of SEQ ID No. 4 or SEQ ID No. 5.

### Claim 21 (depends on 1)

A test kit suitable for carrying out the transcription based amplification and detection of HBV DNA according to claim 1 comprising a restriction enzyme capable of cleaving the HBV DNA at a selected restriction site, said restriction enzyme creating a defined 3′ end of the said HBV DNA strand(s), a forward primer that corresponds with the cleavage site of the restriction enzyme chosen, said forward primer having a 5′ region comprising the sequence of a promoter recognized by a DNA-dependent RNA polymerase and a 3′ region complementary to the defined 3′ end of the DNA strand, and is provided with a promoter sequence, other reagents for carrying out a transcription based amplification reaction, and means for detecting the amplified HBV DNA.

### Claim 22 (depends on 1)

The method according to claim 1, in which the incubation temperature is from about 37° C. to about 41° C.

### Claim 23 (depends on 1)

The method according to claim 1, in which the heating step is carried out at a temperature of about 95° C.

### Claim 24 (depends on 1)

The method according to claim 1, wherein the restriction primer is an oligonucleotide containing from about 15 to about 30 nucleotides which hybridize with the HBV target and comprise at least 15 nucleotides flanking the XbaI site located at nucleotides 247-252 according to the EcoRI site, the BssSI site located at nucleotides 253-258 according to the EcoRI site or the AvrII site located at nucleotides 178-183 according to the EcoRI site.

### Claim 25 (depends on 1)

The method according to claim 1, wherein the promoter or forward primer is an oligonucleotide containing from about 15 to about 30 nucleotides which hybridize with the HBV target and comprising at least 15 nucleotides, counted from the cleavage site, of the nucleotide sequence of SEQ ID No. 10 in combination with the restriction enzyme XbaI, or of SEQ ID No. 11 in combination with BssSI or of SEQ ID No. 12 in combination with AvrII, linked to a promoter sequence.

### Claim 26 (depends on 1)

The method according to claim 1, wherein the amplified HBV nucleic acid is additionally detected using a hybridization probe comprising an oligonucleotide sequence containing from about 15 to about 30 nucleotides which hybridize with the amplified HBV target and comprise at least 15 nucleotides of SEQ ID No. 13 or SEQ ID No. 14.

### Claim 27 (depends on 1)

The method according to claim 1, wherein the second or reverse primer is an oligonucleotide containing from about 15 to about 30 nucleotides and comprising at least 15 nucleotides of the nucleotide sequence of SEQ ID No. 4 or SEQ ID No. 5.

### Claim 28

A set of oligonucleotide primers comprising a promoter primer, wherein the promoter primer is an oligonucleotide containing from about 15 to about 30 nucleotides which hybridize with the HBV target and comprising at least 15 nucleotides, counted from the cleavage site, of the nucleotide sequence of SEQ ID No. 10 in combination with the restriction enzyme XbaI, or of SEQ ID No. 11 in combination with BssSI or of SEQ ID No. 12 in combination with AvrII, linked to a promoter sequence and a reverse primer, wherein the reverse primer is an oligonucleotide containing from about 15 to about 30 nucleotides and comprising at least 15 nucleotides of the nucleotide sequence of SEQ ID No. 4 or SEQ ID No. 5.
